On Thursday shares of Epizyme, Inc. (NASDAQ:EPZM) closed at $17.73. Company’s sales Epizyme, Inc. (NASDAQ:EPZM) announced that data from its preclinical pipeline will be presented during the American Association for Cancer Research (AACR) Annual Meeting, to be held April 18-25 in Philadelphia, Pa.
Prothena Corporation plc (NASDAQ:PRTA) in last trading activity moved down -2.00% to close at $38.28. Company weekly performance is 4.70% while its quarterly performance stands at 84.39%. Prothena Corporation plc (NASDAQ:PRTA) is -14.93% away from its 52 week high.
Prothena Corporation plc (NASDAQ:PRTA) had its target price boosted by RBC Capital from $40.00 to $50.00 in a report issued on Friday. They currently have an outperform rating on the stock.
OXiGENE, Inc. (NASDAQ:OXGN) in last trading activity moved down -1.37% to close at $1.44. Company weekly performance is 3.60% while its quarterly performance stands at -10.56%. OXiGENE, Inc. (NASDAQ:OXGN) is -63.27% away from its 52 week high. OXiGENE, Inc. (NASDAQ:OXGN) said that, it will participate in the 14th Annual Needham Healthcare Conference on April 15, 2015. The presentation will take place at 3:00 p.m. ET at The Westin NY Grand Central Hotel in New York, NY.
Pepsico, Inc. (NYSE:PEP) has 0.20% insider ownership while its institutional ownership stands at 71.20%. In last trading activity company’s stock closed at $95.69. On 3 April, Pepsico, Inc. (NYSE:PEP) commissioned phase one of its Rs. 1,200-crore manufacturing plant at Sri City multi-product economic zone located in Chittoor district of Andhra Pradesh.
On last trading day Pfizer Inc. (NYSE:PFE) moved up 0.15% to close at $34.38. Its volatility for the week is 1.49% while volatility for the month is 1.52%. PFE’s sales growth for past 5 years was 0.10% and its EPS growth for past 5 years was 3.10%. Pfizer Inc. (NYSE:PFE) monthly performance is -0.75%. Pfizer Inc. (NYSE:PFE) said that BIND Therapeutics, Inc., announced an extension of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline.